CVS Health to broaden GLP-1 access as regulators press on pharmacy benefit practices

CVS Health is indicating a renewed effort to give patients broader access to GLP-1 weight management therapies, a category that has helped reshape demand for pharmacy services across the United States. The retailer-pharmacy chain’s latest moves come as regulators and courts continue to examine how pharmacy benefit managers handle coverage, pricing, and reimbursement for expensive prescription drugs.

In reported changes to its formularies, CVS will restore coverage for Eli Lilly’s injectable GLP-1 weight loss drug Zepbound after a new pricing arrangement is reached, with the restoration tied to a future effective date. Separately, CVS is also expected to add a new oral GLP-1 weight management therapy, Foundayo, expanding options beyond injections.

MSN, citing its reporting, said CVS plans to add Foundayo on June 1 and restore Zepbound coverage on October 1, after completing coverage steps linked to its pricing framework. Neither the detailed terms of those pricing changes nor the exact patient impact were outlined in the available reports, leaving questions about how quickly access may improve for specific plans, employer groups, or individual customers.

The timing matters because coverage decisions directly affect whether patients can obtain GLP-1 medications without delays. For pharmacies and PBM-linked businesses, demand is often driven not only by clinical interest in the drugs, but also by whether insurers cover them on preferred tiers and whether prior authorization requirements are applied consistently.

Beyond access, CVS’s broader PBM business faces intensified scrutiny. Pharmacy benefit management has come under repeated regulatory pressure for years, including challenges related to drug reimbursement and patient out-of-pocket costs, as well as allegations that certain plan designs or contracting practices limit access or steer patients toward higher-cost pathways. In that environment, coverage actions around high-demand GLP-1 products can become a proxy for how PBMs are responding to enforcement and litigation risk.

For CVS, GLP-1s are economically significant because they concentrate both volume and cost. These therapies are expensive relative to many chronic prescriptions, and they can influence total pharmacy spend, pharmacy reimbursement rates, and the negotiating leverage PBMs use with manufacturers and plan sponsors. Expanding both injectable and oral options could help CVS reduce friction in care pathways, but it may also require further adjustments in contracting and benefit design.

What remains unclear is how CVS’s access changes translate into member-level coverage outcomes, such as whether prior authorization criteria will be tightened or relaxed and how formularies will treat competing GLP-1 products. The available reporting also does not provide figures on expected utilization, reimbursement economics, or the specific mechanics of any “new pricing” referenced for Zepbound.

Investors and industry watchers will likely focus next on whether CVS’s coverage updates reduce policy-related uncertainty and whether any regulators or courts respond with additional requirements for PBM practices. In the near term, the company may also be judged by execution as the scheduled dates for Foundayo and Zepbound coverage approach and as patient demand continues to test pharmacy inventories and benefit administrators’ rules.